Σύγκριση μεθόδων

	Ερωτηματολόγιο Φλεγμονώδους Νόσου του Εντέρου	ΕΟΚΕ ΠΟΙΟΤΗΤΑ ΖΩΗΣ-C30
Πεδίο	Εκβάσεις Υγείας	Εκβάσεις Υγείας
Οικογένεια	Process / pipeline	Process / pipeline
Έτος προέλευσης	1994	1993
Δημιουργός	Elena J. Irvine et al.	Nico Aaronson et al.
Τύπος	Self-report quality of life questionnaire	Self-report quality of life questionnaire
Θεμελιώδης πηγή	Guyonnet, S., Dupont, C., Mouterde, O., Chouraqui, J. P., Darmaun, D., & Goulet, O. (2001). Placebo-controlled trial of saccharomyces boulardii in gastroenteritis. Pediatrics, 107(2), E27.	Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., ... & Takeda, F. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376.
Εναλλακτικές ονομασίες	IBDQ, IBD Questionnaire, Inflammatory Bowel Disease QoL	QLQ-C30, EORTC QLQ-C30, Cancer Quality of Life Scale
Συναφείς	4	5
Σύνοψη	The IBDQ is a disease-specific quality of life measure for inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Developed by Elena Irvine and colleagues in 1994, this 32-item questionnaire measures how IBD affects bowel function, systemic symptoms, emotional well-being, and social functioning. It is the most widely used quality-of-life instrument in IBD research and clinical practice.	The EORTC QLQ-C30 is the most widely used international instrument for assessing quality of life in cancer patients. Developed by the European Organisation for Research and Treatment of Cancer in 1993, it measures physical, emotional, cognitive, and social functioning alongside cancer-specific symptoms and financial impact, making it the standard outcome measure in oncology clinical trials and patient care.